

## METHODOLOGICAL NOTE

### Introduction

Ferring regularly works with HCP/HCOs and this Methodological note provides a summary of the methodologies used by Ferring in line with the ABPI Code of Practice 2021 to report on Transfers of Value between Ferring and HCP/HCOs. It defines the relevant types of transfers to be disclosed, and other relevant information to assist the reader to understand how Ferring reported the disclosed data.

### Definitions

#### HCP:

includes members of the medical, pharmacy and nursing professions and any other persons, who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. It also includes 'other relevant decision makers', particularly those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals. The primary practice or principal professional address of the HCP is in United Kingdom.

HCO: Any legal entity (i) that is a healthcare, medical or scientific association or organization (irrespective of the legal or organizational form) such as a hospital, clinic, foundation, university or other teaching institution or learned society (except for patient organizations) whose business address, place of incorporation or primary place of operation is in the United Kingdom or (ii) through which one or more HCPs provide services in the United Kingdom

TOV: Transfer of Value - Direct and indirect TOV, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development and sale of prescription only medicine exclusively for human use. Direct TOVs are those made directly by Ferring for the benefit of a Recipient. Indirect TOVs are those made on behalf of Ferring for the benefit of a Recipient, or those made through a Third Party and where Ferring knows or can identify the Recipient that will benefit from the Transfer of Value.

Recipients – any HCO or HCP whose primary practice, main professional address or place of incorporation is in the United Kingdom.

### Disclosure scope

For the 2023 TOV disclosure, data in respect of 2022 is inputted into the ABPI disclosure template from Financial Agreements/contracts made with the HCP/HCO

Excluded ToVs. The following ToVs are excluded under the Code from disclosure: i) those solely related to over-the-counter medicines; ii) those that are part of the ordinary course of business purchases and sales of medicines (for example, between Ferring and a pharmacy); iii) medical samples and investigational compounds for study; iv) informational or educational materials and items of medical utility, v) patient organisations vi) meals and drinks

ToV Recognition Date. ToVs are disclosed based on the date the ToV was paid in our finance systems.



The following types of ToVs to HCO's are disclosed:

- i) donations, grants and benefits in kind provided to institutions, organisations and associations that support healthcare;
- ii) contributions towards the costs related to Events, paid to HCOs or to third parties managing events on their behalf, including sponsorship of HCP's to attend Events, such as: registration fees, travel and accommodations
- iii) fees for service and related expenses paid to a HCP or to their employer on their behalf
- iv) Collaborative Working (which includes Joint Working)
- v) Contracts between companies and institutions, organisations or associations of HCPs under which such institutions, organisations or associations provide any type of services on behalf of Ferring for the purpose of supporting research or educational services.

The following types of ToVs to HCP's are disclosed:

- i) contributions to costs related to Events such as: registration fees, and travel and accommodations (such as costs of flights, trains, taxis and hotel accommodation);
- ii) fees for service and consultancy (examples include speaker fees, speaker training, medical writing, data analysis, general consulting and advising via advisory boards/expert input, fees for participating in market research when the identity of the HCP is known to Ferring.

In case of a HCP cancellation, no ToV will be disclosed.

Disclosing entities. This annual disclosure report covers all ToVs made to HCO's, HCP's and Third Party Organisations in the United Kingdom, whether by Ferring (UK) Limited or by its affiliates based in other countries.

Cross-border activities. Regardless of which Ferring entity contracts with or pays a Recipient, all HCO's or HCP's whose primary practice, main professional address or place of incorporation is in the United Kingdom are reported by Ferring.

### **Consent management**

Consent to provide disclosure information of transfer of values is obtained as a part of the financial agreement/contract completed by the HCP/HCO with a clear GDPR disclaimer.

A Recipient has the right to withdraw their consent at any time

### **Tax considerations**

It is the responsibility of the HCP/HCO to inform tax authorities of payments received as transfer of values from Ferring. Ferring is not responsible for providing information to tax authorities regarding payments made to HCPs and HCOs.

VAT is not included in the payments.

### **Currency aspects**



Conversion rates: All 2022 payments were made either in UK Pounds or Euros. Euro entries were converted to UK Pounds by Ferring on the 21<sup>st</sup> March 2023

### **Multi-year contracts**

Only contracts with ToV where the payment was actually made in 2022 have been included in the 2022 disclosure. For contracts where the invoices are paid out in 2023, the disclosure will be made in 2023.